Monte Rosa Therapeutics宣布临床供应协议 支持MRT-2359联合阿帕鲁胺治疗转移性去势抵抗性前列腺癌的二期试验
投资观察
Mar 16
Monte Rosa Therapeutics公司宣布达成一项临床供应协议,旨在支持评估MRT-2359联合阿帕鲁胺治疗转移性去势抵抗性前列腺癌的二期临床试验。
根据协议,Monte Rosa Therapeutics计划于2026年第三季度启动MRT-2359与阿帕UTAMIDE的二期研究。该公司已与强生公司签署供应协议,为这项定于2026年第三季度开始的转移性去势抵抗性前列腺癌二期研究提供支持。
Monte Rosa Therapeutics将负责开展并资助该试验;强生公司将供应其药物阿帕鲁胺。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.